Experts from ASCO and AACR have penned a statement for policymakers on the potential negative effects of e-cigarettes and other nicotine-deliveries electronics.
Practice & Policy
Risk for febrile neutropenia was high among patients with metastases from a variety of common cancers and was associated with numerous clinical and economic consequences, including increased morbidity and mortality.
Patient satisfaction data can give practices insight into their operations and make specific, practice-level adjustments accordingly, and with aggregated data we can gain insights into global practice responsiveness and patient perceptions regarding care.
A panel of experts has put together a guide to implementing shared decision-making that provides tips for integrating the model into busy oncology practices.
ASCO is calling for major reforms to the Medicaid system in order to close gaps in cancer coverage and improve quality of care for low-income Americans.
NLST data clearly demonstrate that lung cancer screening is effective and safe and reduces lung cancer-specific mortality by at least 20%. There is no possible reason for CMS to further delay or restrict lung cancer screening for those at high risk.
The development of CT lung cancer screening, the publication of results from the NLST in 2011, and the grade-B recommendation for CT lung cancer screening in high-risk smokers by the USPSTF raise a number of interesting national health policy issues.
The NLST is a landmark trial demonstrating that implementation of low-dose CT screening lowers lung cancer–related mortality. We must put the study results and cost-effectiveness analyses in the context of the staggering statistics: up to 65% of lung cancer patients present with advanced-stage disease where treatments are often costly, toxic, and only palliative in nature.
American medicine is poised for an expanded conflict over the assumption and consequences of risk in medical care.
The Centers for Medicare & Medicaid Services announced plans to cover low-dose CT screening for lung cancer, based mainly on the National Lung Screening Trial.